836 related articles for article (PubMed ID: 30010043)
21. Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
Zheng J; Zhu Y; Sun K; Shen Q; Wang Y; Cao H; Lizaso A; Yu B; Lin J; Chen S; Zhou J; Zhou J
Lung Cancer; 2020 Aug; 146():209-216. PubMed ID: 32563740
[TBL] [Abstract][Full Text] [Related]
22. Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
Kuang Y; Xu P; Wang J; Zheng Y; Sun X; Li Z; Gan R; Li H; Guo Y; Yao F; Zhu C; Ke Z; Tang K
Mol Diagn Ther; 2021 Jul; 25(4):487-494. PubMed ID: 34133003
[TBL] [Abstract][Full Text] [Related]
23. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
[TBL] [Abstract][Full Text] [Related]
25. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract][Full Text] [Related]
26. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
28. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
[TBL] [Abstract][Full Text] [Related]
29. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
[TBL] [Abstract][Full Text] [Related]
30. Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC.
Zhang Y; Zeng L; Zhou C; Li Y; Wu L; Xia C; Jiang W; Hu Y; Liao D; Xiao L; Liu L; Yang H; Xiong Y; Guan R; Lizaso A; Mansfield AS; Yang N
J Thorac Oncol; 2020 Jun; 15(6):1027-1036. PubMed ID: 32112982
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological characteristics of patients with surgically resected lung cancer having tumours harboring anaplastic lymphoma kinase fusion protein.
Chen B; Jiang Z; Li C; Lu H
J Pak Med Assoc; 2020 Apr; 70(4):747-750. PubMed ID: 32296229
[TBL] [Abstract][Full Text] [Related]
32. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
[TBL] [Abstract][Full Text] [Related]
33. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract][Full Text] [Related]
34. The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement.
Bilgin B; Şendur MAN; Yücel Ş; Hizal M; Güner G; Akyürek N; Erol C; Akıncı MB; Dede DŞ; Yalçın B; Kılıçkap S
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2637-2643. PubMed ID: 33528638
[TBL] [Abstract][Full Text] [Related]
35. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
Pagan C; Barua S; Hsiao SJ; Mansukhani M; Saqi A; Murty V; Fernandes H
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.
Xu CW; Wang WX; Chen YP; Chen Y; Liu W; Zhong LH; Chen FF; Zhuang W; Song ZB; Chen XH; Huang YJ; Guan YF; Yi X; Lv TF; Zhu WF; Lu JP; Wang XJ; Shi Y; Lin XD; Chen G; Song Y
J Transl Med; 2018 Apr; 16(1):93. PubMed ID: 29642919
[TBL] [Abstract][Full Text] [Related]
37. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
Hembrough T; Liao WL; Hartley CP; Ma PC; Velcheti V; Lanigan C; Thyparambil S; An E; Monga M; Krizman D; Burrows J; Tafe LJ
Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
[TBL] [Abstract][Full Text] [Related]
38. Development of a novel ALK rearrangement screening test for non-small cell lung cancers.
Chen YL; Chen WL; Cheng YC; Lin MC; Yang SC; Tsai HW; Lin CC; Su WC; Chow NH; Ho CL
PLoS One; 2021; 16(9):e0257152. PubMed ID: 34559836
[TBL] [Abstract][Full Text] [Related]
39. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
[TBL] [Abstract][Full Text] [Related]
40. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]